One result of the rimonabant problems was that the market forecast for pharmaceutical treatment of obesity immediately dropped, as the US would have been the largest market for this drug; that dampening of the market is reflected in …

article continues at P. Driscoll brought to you by diabetes.medtrials.info and medtrials.info